2 weeks Ago By Defense World Staff
Wellington Wealth Strategies LLC. purchased a new position in shares of Abbott Laboratories ( NYSE:ABT – Free Report ) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,213 shares of the healthcare product maker’s stock, valued at approximately $334,000.
Abbott Laboratories makes up about 1.5% of Wellington Wealth Strategies LLC.’s holdings, making the stock its 15th biggest holding.
A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 5.
6% in the first quarter. Vanguard Group Inc. now owns 165,301,921 shares of the healthcare product maker’s stock valued at $18,788,216,000 after purchasing an additional 8,834,840 shares during the period.
Capital Research Global Investors grew its holdings in Abbott Laboratories by 9.5% in the fourth quarter. Capital Research Global Investors now owns 86,588,614 shares of the healthcare product maker’s stock valued at $9,530,825,000 after purchasing an additional 7,527,778 shares during the period.
Capital International Investors boosted its holdings in shares of Abbott Laboratories by 9.1% in the 1st quarter. Capital International Investors now owns 70,177,564 shares of the healthcare product maker’s stock valued at $7,976,382,000 after purchasing an additional 5,882,780 shares during the last quarter.
Wellington Management Group LLP grew its stake in shares of Abbott Laboratories by 3.3% during the 4th quarter. Wellington Management Group LLP now owns 32,236,101 shares of the healthcare product maker’s stock valued at $3,548,228,000 after buying an additional 1,027,390 shares during the period.
Finally, Ameriprise Financial Inc. boosted its holdings in Abbott Laboratories by 5.0% in the second quarter.
Ameriprise Financial Inc. now owns 10,675,827 shares of the healthcare product maker’s stock valued at $1,103,997,000 after acquiring an additional 508,524 shares during the last quarter. Institutional investors and hedge funds own 75.
18% of the company’s stock. Wall Street Analyst Weigh In A number of brokerages have recently issued reports on ABT. Barclays boosted their target price on Abbott Laboratories from $140.
00 to $143.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, July 30th.
Citigroup boosted their price objective on Abbott Laboratories from $119.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd.
Jefferies Financial Group reiterated a “hold” rating and issued a $120.00 target price on shares of Abbott Laboratories in a research note on Thursday. Finally, Piper Sandler started coverage on Abbott Laboratories in a research report on Thursday, September 19th.
They set an “overweight” rating and a $131.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company.
According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.00. Insider Transactions at Abbott Laboratories In related news, CEO Robert B.
Ford sold 141,679 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total transaction of $16,492,852.
39. Following the sale, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19.
The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . Insiders own 1.10% of the company’s stock.
Abbott Laboratories Stock Performance Abbott Laboratories stock opened at $112.43 on Monday. The company has a current ratio of 1.
68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.
The stock has a 50 day moving average of $111.57 and a 200-day moving average of $108.19.
The stock has a market cap of $195.59 billion, a P/E ratio of 35.02, a price-to-earnings-growth ratio of 2.
86 and a beta of 0.72. Abbott Laboratories has a 52 week low of $89.
67 and a 52 week high of $121.64. Abbott Laboratories ( NYSE:ABT – Get Free Report ) last released its earnings results on Thursday, July 18th.
The healthcare product maker reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.
04. The company had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.
37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.
18%. The company’s revenue was up 4.0% on a year-over-year basis.
During the same quarter in the previous year, the firm earned $1.08 EPS. On average, analysts expect that Abbott Laboratories will post 4.
66 EPS for the current fiscal year. Abbott Laboratories Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a dividend of $0.
55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 1.
96%. The ex-dividend date is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 68.
54%. Abbott Laboratories Company Profile ( Free Report ) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. See Also Five stocks we like better than Abbott Laboratories 3 Fintech Stocks With Good 2021 Prospects Simon Property REIT: A Safe Bet for Growth and Steady Dividends How to Capture the Benefits of Dividend Increases CarMax’s Impressive Rally: What Investors Should Watch Next How to Evaluate a Stock Before Buying MarketBeat Week in Review – 9/23 – 9/27 Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories ( NYSE:ABT – Free Report ).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter ..
